GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
GALECTIN THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.50−0.13 (-3.45%)
Close on Oct 19, 2026
- Market cap
- $230.23M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
15.6%
16M of 101M shares
Institutional holders
98
20 new, 20 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
6 buys · 67 sales
Net sold $6.68M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| James C. Czirr | 7,061,115 | 11.40% | 13D (active) amendment | Sep 22, 2023 |
| Richard E. Uihlein | 54,673,646 | 49.30% | 13D (active) amendment | Jul 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GALT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,988,353 | 2.96% | $13.87M | +2,189,116 | 0.00% |
| Vanguard Capital Management LLC | 2,168,065 | 2.15% | $10.06M | +201,523 | 0.00% |
| Geode Capital Management, LLC | 1,308,394 | 1.30% | $6.07M | +695,608 | 0.00% |
| Osaic Holdings, Inc. | 1,203,725 | 1.19% | $5.59M | +81,055 | 0.01% |
| Marshall Wace, Llp | 831,010 | 0.82% | $3.86M | −388,902 | 0.00% |
| Wealthspire Advisors, LLC | 721,788 | 0.72% | $3.35M | – | 0.02% |
| State Street Corp | 567,779 | 0.56% | $2.63M | +309,347 | 0.00% |
| Commonwealth Equity Services, LLC | 407,113 | 0.40% | $1.89M | +40,000 | 0.00% |
| Northern Trust Corp | 386,545 | 0.38% | $1.79M | +256,097 | 0.00% |
| Vanguard Fiduciary Trust Co | 366,476 | 0.36% | $1.70M | +62,235 | 0.00% |
| Vanguard Portfolio Management LLC | 327,766 | 0.33% | $1.52M | New | 0.00% |
| Two Sigma Investments, LP | 318,245 | 0.32% | $1.48M | −148,818 | 0.00% |
| LPL Financial LLC | 285,380 | 0.28% | $1.32M | +18,180 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 261,296 | 0.26% | $1.21K | +132,648 | 0.00% |
| Sovran Advisors, LLC | 257,997 | 0.26% | $874.61K | +167 | 0.07% |
| Geneos Wealth Management Inc. | 240,427 | 0.24% | $1.12M | −500 | 0.02% |
| UBS Group AG | 219,319 | 0.22% | $1.02M | +39,578 | 0.00% |
| Retirement Guys Formula LLC | 211,053 | 0.21% | $979.29K | +23,991 | 0.37% |
| Citadel Advisors LLC | 198,701 | 0.20% | $921.97K | −91,659 | 0.00% |
| Susquehanna International Group, Llp | 177,197 | 0.18% | $822.19K | −378,505 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 98 | 16M | 15.6% | 20 / 32 | 23 / 20 | 5M | 3M |
| Q1 2026 | 99 | 14M | 13.8% | 19 / 31 | 23 / 15 | 6M | 1M |
| Q4 2025 | 98 | 12M | 11.5% | 25 / 28 | 22 / 10 | 2M | 1M |
| Q3 2025 | 84 | 10M | 10.3% | 15 / 22 | 25 / 16 | 2M | 2M |
| Q2 2025 | 86 | 11M | 10.4% | 15 / 25 | 20 / 21 | 2M | 2M |
| Q1 2025 | 93 | 10M | 10.3% | 14 / 18 | 30 / 12 | 1M | 1M |
| Q4 2024 | 94 | 10M | 10.0% | 21 / 35 | 12 / 6 | 1M | 1M |
| Q3 2024 | 79 | 10M | 9.7% | 14 / 20 | 18 / 4 | 2M | 0M |
| Q2 2024 | 73 | 10M | 9.4% | 23 / 19 | 10 / 9 | 2M | 1M |
| Q1 2024 | 59 | 8M | 7.9% | 4 / 18 | 9 / 11 | 1M | 0M |
| Q4 2023 | 66 | 7M | 7.3% | 9 / 10 | 16 / 3 | 1M | 2M |
| Q3 2023 | 60 | 9M | 9.0% | 5 / 12 | 9 / 4 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GALT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,521,443 | 1.51% | $7.06M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 951,470 | 0.94% | $4.41M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 594,705 | 0.59% | $2.76M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 520,365 | 0.52% | $1.55M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 309,874 | 0.31% | $1.44M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 271,585 | 0.27% | $684.39K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 160,592 | 0.16% | $745.15K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 116,397 | 0.12% | $345.70K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 112,988 | 0.11% | $524.26K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 95,489 | 0.09% | $240.63K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 89,577 | 0.09% | $415.64K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 78,302 | 0.08% | $197.32K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 63,710 | 0.06% | $189.22K | 0.00% | Jul 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 48,031 | 0.05% | $222.86K | 0.00% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 47,686 | 0.05% | $221.26K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joel Lewis | President and CEO, Director | 778,260 | 0.77% | Jan 22, 2026 |
| Khurram Jamil | Chief Medical Officer | 16,250 | 0.02% | Jul 16, 2026 |
| Jack W. Callicutt | Chief Financial Officer | 7,614 | 0.01% | Jan 21, 2026 |
| Richard E. Uihlein | Director, 10% owner | 52,523,297 | 52.08% | Aug 4, 2026 |
| Harold H. Shlevin | Director | 28,768 | 0.03% | Jun 30, 2026 |
| Henry Brem | Director | 0 | – | Mar 17, 2026 |
| Kary Eldred | Director | 70,107 | 0.07% | Feb 9, 2026 |
| Benjamin Carson Sr | Director | – | – | Jan 21, 2026 |
| Gilbert F. Amelio | Director | 60,614 | 0.06% | Jan 21, 2026 |
| Gilbert S. Omenn | Director | 66,769 | 0.07% | Jan 21, 2026 |
| Elissa J. Schwartz | Director | 1,000 | 0.00% | Jan 21, 2026 |
| Richard A. Zordani Jr. | Director | 44,083 | 0.04% | Jan 21, 2026 |
| Kevin D. Freeman | Director | 137,269 | 0.14% | Jan 21, 2026 |
| Marc Rubin | Director | 13,581 | 0.01% | Jan 27, 2025 |
| 10X Fund, L.P. | 10% owner | 12,091,147 | 11.99% | Dec 18, 2025 |
| James C. Czirr | 10% owner | 11,536,664 | 11.44% | Dec 18, 2025 |
| 10X Capital Management, LLC | 10% owner | 8,319,924 | 8.25% | Dec 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard E. Uihlein Director, 10% owner | Jul 31, 2026 | Option exercise | +31,825,235 | $3.00 | $95.48M | 42,162,911 |
| Richard E. Uihlein Director, 10% owner | Jul 31, 2026 | Option exercise | +2,550,932 | $4.05 | $10.33M | 44,713,843 |
| Khurram Jamil Chief Medical Officer | Jul 14, 2026 | Option exercise | +16,250 | $3.04 | $49.40K | 16,250 |
| Khurram Jamil Chief Medical Officer | Jul 14, 2026 | Sale(10b5-1 plan) | −16,250 | $5.13 | $83.36K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 29, 2026 | Option exercise | +47,467 | $2.50 | $118.67K | 47,467 |
| Khurram Jamil Chief Medical Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −47,467 | $5.04 | $239.23K | 0 |
| Harold H. Shlevin Director | Jun 29, 2026 | Option exercise | +22,268 | $1.23 | $27.39K | 28,768 |
| Harold H. Shlevin Director | Jun 29, 2026 | Sale(10b5-1 plan) | −22,268 | $5.04 | $112.23K | 6,500 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Option exercise | +2,533 | $2.50 | $6.33K | 2,533 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −2,533 | $5.00 | $12.67K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −2,037 | $5.00 | $10.19K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 26, 2026 | Option exercise | +2,037 | $2.20 | $4.48K | 2,037 |
| Harold H. Shlevin Director | Jun 26, 2026 | Sale(10b5-1 plan) | −7,732 | $5.00 | $38.66K | 6,500 |
| Harold H. Shlevin Director | Jun 26, 2026 | Option exercise | +7,732 | $1.23 | $9.51K | 14,232 |
| Khurram Jamil Chief Medical Officer | Jun 23, 2026 | Sale(10b5-1 plan) | −7,557 | $3.14 | $23.73K | 0 |
| Khurram Jamil Chief Medical Officer | Jun 23, 2026 | Option exercise | +7,557 | $1.23 | $9.30K | 7,557 |
| Khurram Jamil Chief Medical Officer | May 26, 2026 | Option exercise | +568 | $1.23 | $699 | 568 |
| Khurram Jamil Chief Medical Officer | May 26, 2026 | Sale(10b5-1 plan) | −568 | $3.10 | $1.76K | 0 |
| Kary Eldred Director | Feb 6, 2026 | Buy | +300 | $2.70 | $810 | 65,682 |
| Richard E. Uihlein Director, 10% owner | Jan 16, 2026 | Award | +13,158 | $3.04 | $40.00K | 10,332,676 |
| Jack W. Callicutt Chief Financial Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −20,354 | $3.67 | $74.70K | 7,614 |
| Joel Lewis President and CEO, Director | Jan 6, 2026 | Sale(10b5-1 plan) | −37,698 | $3.58 | $134.96K | 832,592 |
| Khurram Jamil Chief Medical Officer | Jan 6, 2026 | Sale(10b5-1 plan) | −21,446 | $3.65 | $78.28K | 0 |
| Joel Lewis President and CEO, Director | Jan 5, 2026 | – | −56,332 | $3.88 | $218.57K | 776,260 |
| Jack W. Callicutt Chief Financial Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −25,732 | $3.90 | $100.35K | 27,968 |
| Joel Lewis President and CEO, Director | Jan 5, 2026 | Sale(10b5-1 plan) | −27,731 | $3.91 | $108.43K | 870,290 |
| Khurram Jamil Chief Medical Officer | Jan 5, 2026 | Sale(10b5-1 plan) | −25,499 | $3.90 | $99.45K | 21,446 |
| Jack W. Callicutt Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −13,914 | $4.20 | $58.44K | 53,700 |
| Jack W. Callicutt Chief Financial Officer | Jan 2, 2026 | Option exercise | +60,000 | – | – | 67,614 |
| Joel Lewis President and CEO, Director | Jan 2, 2026 | Sale(10b5-1 plan) | −18,571 | $4.20 | $78.00K | 898,021 |
| Joel Lewis President and CEO, Director | Jan 2, 2026 | Option exercise | +84,000 | – | – | 916,592 |
| Khurram Jamil Chief Medical Officer | Jan 2, 2026 | Option exercise | +60,000 | – | – | 60,000 |
| Khurram Jamil Chief Medical Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −13,055 | $4.20 | $54.83K | 46,945 |
| Khurram Jamil Chief Medical Officer | Dec 31, 2025 | Sale(10b5-1 plan) | −8,125 | $4.07 | $33.07K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 31, 2025 | Option exercise | +8,125 | $1.23 | $9.99K | 8,125 |
| Kary Eldred Director | Dec 23, 2025 | Buy | +700 | $3.73 | $2.61K | 65,382 |
| Kevin D. Freeman Director | Dec 23, 2025 | Buy | +5,500 | $3.55 | $19.53K | 55,269 |
| Kevin D. Freeman Director | Dec 23, 2025 | Buy | +5,500 | $3.55 | $19.53K | 55,269 |
| Kary Eldred Director | Dec 23, 2025 | Buy | +700 | $3.73 | $2.61K | 65,382 |
| Kevin D. Freeman Director | Dec 23, 2025 | Buy | +5,500 | $3.55 | $19.53K | 55,269 |
| Harold H. Shlevin Director | Dec 17, 2025 | Sale(10b5-1 plan) | −19,793 | $7.04 | $139.34K | 11,206 |
| Harold H. Shlevin Director | Dec 17, 2025 | Sale(10b5-1 plan) | −4,706 | $7.04 | $33.13K | 6,500 |
| Harold H. Shlevin Director | Dec 17, 2025 | Option exercise | +20,000 | $1.98 | $39.60K | 31,206 |
| Joel Lewis President and CEO, Director | Dec 17, 2025 | Option exercise | +7,829 | $2.86 | $22.39K | 840,421 |
| Joel Lewis President and CEO, Director | Dec 17, 2025 | Sale(10b5-1 plan) | −7,829 | $7.06 | $55.27K | 832,592 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −4,479 | $7.04 | $31.53K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −6,463 | $7.04 | $45.50K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Option exercise | +8,500 | $2.50 | $21.25K | 8,500 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Sale(10b5-1 plan) | −8,500 | $7.04 | $59.84K | 0 |
| Khurram Jamil Chief Medical Officer | Dec 17, 2025 | Option exercise | +6,463 | $2.20 | $14.22K | 6,463 |
| James C. Czirr 10% owner | Dec 16, 2025 | Sale | −30,681 | $6.66 | $204.34K | 5,614,457 |
| Harold H. Shlevin Director | Dec 15, 2025 | Sale(10b5-1 plan) | −8,417 | $6.30 | $53.03K | 11,206 |
| Harold H. Shlevin Director | Dec 15, 2025 | Option exercise | +8,417 | $4.16 | $35.01K | 19,623 |
| Harold H. Shlevin Director | Dec 12, 2025 | Option exercise | +19,793 | $4.16 | $82.34K | 30,999 |
| Harold H. Shlevin Director | Dec 12, 2025 | Sale(10b5-1 plan) | −19,793 | $6.27 | $124.10K | 11,206 |
| Harold H. Shlevin Director | Dec 9, 2025 | Sale(10b5-1 plan) | −16,790 | $6.27 | $105.27K | 11,206 |
| Harold H. Shlevin Director | Dec 9, 2025 | Option exercise | +16,790 | $4.16 | $69.85K | 27,996 |
| Harold H. Shlevin Director | Dec 8, 2025 | Sale(10b5-1 plan) | −20,000 | $6.00 | $120.00K | 11,206 |
| Harold H. Shlevin Director | Dec 8, 2025 | Option exercise | +20,000 | $1.11 | $22.20K | 31,206 |
| Harold H. Shlevin Director | Dec 8, 2025 | Sale(10b5-1 plan) | −35,000 | $6.02 | $210.70K | 11,206 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shlevin Harold Director | Jun 29, 2026 | 22,268 | $112.21K | Jun 29, 2026 | STOCK OPTION EXERCISE |
| Shlevin Harold DIRECTOR | Jun 26, 2026 | 7,732 | $38.68K | Jun 26, 2026 | STOCK OPTION EXERCISE |
| Khurram Jamil Officer | Jun 26, 2026 | 68,287 | $341.44K | Jun 26, 2026 | Stock Option Exercise |
| Khurram Jamil Officer | Jun 23, 2026 | 8,125 | $25.50K | Jun 23, 2026 | Stock Option Exercise |
| Harold H. Shlevin Director | Jan 6, 2026 | 441,500 | $1.84M | Jan 2, 2026 | PURCHASE |
| Jack W. Callicutt Officer | Jan 5, 2026 | 60,000 | $252.00K | Jan 2, 2026 | Restricted Stock Units |
| Joel Lewis Officer | Jan 2, 2026 | 84,000 | $352.80K | Jan 2, 2026 | Restricted Stock Units |
| Khurram Jamil Officer | Jan 2, 2026 | 60,000 | $252.00K | Jan 2, 2026 | Restricted Stock Units |
| Jack W. Callicutt Officer | Jan 2, 2026 | 141,206 | $593.07K | Jan 2, 2026 | Restricted Stock Units |
| Khurram Jamil Officer | Dec 31, 2025 | 8,125 | $33.31K | Dec 31, 2025 | Option Exercise |
| Joel Lewis Officer | Dec 17, 2025 | 40,000 | $282.24K | Dec 17, 2025 | Option Exercise |
| Khurram Jamil Officer | Dec 17, 2025 | 21,479 | $151.21K | Dec 17, 2025 | Option Exercise |
| Shlevin Harold DIRECTOR | Dec 17, 2025 | 24,706 | $172.22K | Dec 17, 2025 | STOCK OPTION |
| Shlevin Harold DIRECTOR | Dec 15, 2025 | 19,793 | $122.99K | Dec 12, 2025 | STOCK OPTION |
| Shlevin Harold DIRECTOR | Dec 15, 2025 | 8,417 | $52.54K | Dec 15, 2025 | STOCK OPTION |